Skip to main content

Table 1 Patient characteristics and clinical course in each group

From: A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma

Parameters LA (n = 28) CY (n = 16) P (n = 13) L (n = 10)
Gender (M/F) 14:14 11:5 6:7 6:4
Age (years) 66 (47–82) 63 (41–85) 69 (42–78) 63 (55–75)
PS 0/1 vs 2 26:2 16:0 12:1 8:2
Location (Pbt/Ph) 11:17 (39) 6:10 (38) 10:3 (77) 6:4 (60)
Tumor size (mm) 41 (23–76) 41 (27–91) 47 (21–88) 37 (28–85)
Size > 39.5 vs low 15:13 9:7 9:4 3:7
DM (yes/no) 5:23 3:13 5:8 4:6
Obstructive jaundice (yes/no) 15:13 7:9 4:9 5:5
Bilirubin (mg/dl) 0.8 (0.3–10) 0.7 (0.4–2.8) 0.6 (0.4–1.3) 0.9 (0.5–1.8)
Albumin (g/l) 3.6 (2.3–4.5) 3.8 (2.9–4.6) 4.0 (2.7–4.6) 4.0 (3.3–4.7)
Hemoglobin (g/dl) 11.7 (8–14.7) 11.9 (10.5–14.9) 12.4 (10.2–14.8) 13.3 (11–14.9)
CA19-9 (IU/l) 232 (1–3978) 371 (18–13,400) 385 (6–18,977) 997 (66–34,408)
CTx vs BSC 23:5 16:0 9:4 9:1
Duration of CTx (months) 7.5 (0–64) 10 (1.5–53) 3 (0–10) 6 (0–17)
GS (yes/no) 12:16 7:9 2:11 3:7
Radiation (yes/no) 15:13 5:11 0:13 0:10
Second-line chemotherapy (yes/no) 18:10 10:6 1:12 7:3
CR/PR vs SD/PD 9:19 6:10 2:11 2:8
1-year survival rate 50 % 63 % 31 % 20 %
Adjuvant surgery 1/28 2/16 0 0
Development of ascites within 1 year 10/28 (36 %) 7/16 (44 %) 11/13 (85 %) 5/10 (50 %)
  1. Data are expressed as the median (range) or n (%)
  2. LA locally advanced, CY positive cytology, P peritoneal metastasis, L liver metastasis, M male, F female, PS performance status, Ph pancreas head, Pbt pancreas body and tail, DM diabetes mellitus, CA19-9 carbohydrate antigen 19-9, CTx chemotherapy, BSC best supportive care, GS gemcitabine and S-1, CR complete response, PR partial response, SD stable disease, PD progressive disease